Skip to main content

Table 3 Meta-analytic results based on the studies regarding of different design types

From: I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment: a meta-analysis

 

Number of studies

OR or HR (95% CI)

Heterogeneity

Favor

Randomized controlled trial

 CR

2

0.11 (0.03, 0.43), P = 0.001

I2 = 0%

Combined

 TR

2

0.50 (0.21, 1.21), P = 0.13

I2 = 0%

 DC

2

0.38 (0.11, 1.36), P = 0.14

I2 = 0%

 PFS

2

1.80 (1.29, 2.50), P = 0.0005

I2 = 0%

Combined

Retrospective

 CR

4

0.26 (0.15, 0.47), P < 0.00001

I2 = 27%

Combined

 TR

4

0.24 (0.10, 0.58), P = 0.001

I2 = 78%

Combined

 DC

4

0.18 (0.09, 0.36), P < 0.0001

I2 = 9%

Combined

 Myelosuppression

3

0.62 (0.39, 1.00), P = 0.05

I2 = 0%

 Gastrointestinal response

3

0.86 (0.55, 1.35), P = 0.52

I2 = 0%

 PFS

4

1.45 (1.10, 1.90), P = 0.009

I2 = 67%

Combined

 OS

4

1.40 (1.22, 1.60), P < 0.0001

I2 = 0%

Combined

  1. OR odd ratio, HR hazard ratio, CR complete response, TR treatment response, DC disease control, PFS progression-free survival, OS overall survival